Parathyroid hormone (PTH) replacement therapy is superior to conventional treatment at lowering blood phosphate levels and the need for calcium and vitamin D supplements in people with chronic hypoparathyroidism, according to a review of clinical trial data. It appeared to be associated with higher-than-normal calcium levels (hypercalcemia) and had…
News
Persistent hypoparathyroidism after complete removal of the thyroid gland is more common than previously thought, a study in Japan has found. These findings, based on health insurance claims, add to previous reports linking persistent hypoparathyroidism after the surgery (called a total thyroidectomy) with greater risk for renal insufficiency and…
Treatment with AZP-3601, Amolyt Pharma’s experimental therapy for hypoparathyroidism, safely brought calcium levels to within normal ranges in the first group of patients in a Phase 2 clinical trial, the company has announced. Most of the trial participants were able to discontinue standard treatment with calcium and vitamin…
Ascendis Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism, the company announced. “Our data support that TransCon PTH, if approved, could become the first-in-class therapy to address the underlying cause of…
Patients with long-lasting hypoparathyroidism in Sweden are over three times more likely than healthy individuals to develop kidney complications such as chronic kidney disease and kidney stones, and this may translate into more frequent hospital admissions, a study found. The study, “Kidney Complications and Hospitalization in Patients with…
Patients with chronic hypoparathyroidism following surgery for thyroid cancer do not have overall significant cognitive impairments, but those with lower blood calcium levels showed some disruptions in cognitive function, according to a study. Specifically, patients with lower calcium levels exhibited impairments in visuo-spatial attention, semantic memory (memory of general…
Adults with hypoparathyroidism given long-term treatment with Natpara are less likely to experience heart-related health problems, according to an analysis of data from three clinical trials. Natpara “may confer cardiovascular benefits to patients with chronic hypoparathyroidism, and further research is warranted to understand the relationship better in a real-world setting,” the researchers…
MBX 2109, an experimental hormone replacement therapy that MBX Biosciences is developing for hypoparathyroidism, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies intended to treat rare diseases, defined as those that affect less than 200,000 people…
Replacement therapy with either Forteo or Natpara, two versions of the parathyroid hormone (PTH), appears to be safe and effective in controlling calcium and phosphorus pools in the body, and this translates to better quality of life for patients with hypoparathyroidism, a meta-analysis study has found. The study, “…
Calcium citrate was as effective as calcium carbonate at sustaining normal calcium levels in people with hypoparathyroidism, but was associated with fewer gastrointestinal side effects and a potentially lower risk of nephrolithiasis, or kidney stones, according to a study. “These results are likely to have clinical implications in [hypoparathyroidism],…
Recent Posts
- Silent calcium deficiency during pregnancy leads to DiGeorge diagnosis
- Navigating hypopara with the Year of the Horse as my inspiration
- Having hypoparathyroidism helped me view friendships as a ‘spectrum of love’
- Celebrating my one-year anniversary with Hypoparathyroidism News
- Companies team to develop once-a-day hypoparathyroidism pill